The New England Journal of Medicine | Research & Review Articles on ...
The New England Journal of Medicine (NEJM) is a weekly general medical journal that publishes new medical research and review articles, and editorial opinion on a wide variety of topics of ...
Antibiotic Treatment for 7 versus 14 Days in Patients with Bloodstream ...
Nov 20, 2024 · Bloodstream infections are associated with substantial morbidity and mortality. Early, appropriate antibiotic therapy is important, but the duration of treatment is uncertain. In a multicenter, …
Structured Exercise after Adjuvant Chemotherapy for Colon Cancer
Jun 1, 2025 · Methods In this phase 3, randomized trial conducted at 55 centers, we assigned patients with resected colon cancer who had completed adjuvant chemotherapy to participate in a structured …
Phase 3 Trial of the DPP-1 Inhibitor Brensocatib in Bronchiectasis
Apr 23, 2025 · In bronchiectasis, neutrophilic inflammation is associated with an increased risk of exacerbations and disease progression. Brensocatib, an oral, reversible inhibitor of dipeptidyl …
Phase 3 Trial of Semaglutide in Metabolic Dysfunction–Associated ...
Apr 30, 2025 · Semaglutide, a glucagon-like peptide-1 receptor agonist, is a candidate for the treatment of metabolic dysfunction–associated steatohepatitis (MASH). In this ongoing phase 3, multicenter ...
Imlunestrant with or without Abemaciclib in Advanced Breast Cancer
Dec 11, 2024 · Imlunestrant is a next-generation, brain-penetrant, oral selective estrogen-receptor (ER) degrader that delivers continuous ER inhibition, even in cancers with mutations in the gene encoding …
Tarlatamab in Small-Cell Lung Cancer after Platinum-Based …
Jun 2, 2025 · Tarlatamab, a bispecific delta-like ligand 3–directed T-cell engager immunotherapy, received accelerated approval for the treatment of patients with previously treated small-cell lung …
Intensive Blood-Pressure Control in Patients with Type 2 Diabetes
Nov 16, 2024 · Effective targets for systolic blood-pressure control in patients with type 2 diabetes are unclear. We enrolled patients 50 years of age or older with type 2 diabetes, elevated systolic blood …
Efficacy and Safety of Obinutuzumab in Active Lupus Nephritis
Feb 7, 2025 · Methods In a phase 3, randomized, controlled trial, we assigned adults with biopsy-proven active lupus nephritis in a 1:1 ratio to receive obinutuzumab in one of two dose schedules (1000 mg …
Aspirin in Patients with Chronic Coronary Syndrome Receiving Oral ...
Aug 30, 2025 · The appropriate antithrombotic regimen for patients with chronic coronary syndrome who are at high atherothrombotic risk and receiving long-term oral anticoagulation remains unknown. We …